ArticleInternational journal of hematology2026
Real-world effectiveness of fostamatinib in patients with immune thrombocytopenia: a single-center retrospective study.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionImmune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by increased platelet destruction and thrombocytopenia. Fostamatinib inhibits spleen tyrosine kinase and suppresses platelet destruction. However, clinical evidence of its efficacy in Japanese patients with ITP remains limited.
methodsIn this study, we retrospectively evaluated the clinical outcomes of fostamatinib, with or without thrombopoietin receptor agonists (TPO-RAs), at a single center in Japan.
resultsThe study included 11 patients. At week 1, all 3 evaluable patients (100.0%) achieved platelet count ≥ 30,000/μL and a twofold increase from baseline; at week 2, 10 of 11 (90.9%) met the criteria. Ultimately, 10 of 11 (90.9%) patients achieved the criteria at least once within 24 weeks. All 3 patients using concomitant TPO-RAs (100.0%) achieved the primary endpoint. After fostamatinib initiation, 9 of 11 (81.8%) patients discontinued or reduced their concomitant glucocorticoid (GC) dose. Thrombosis was not observed regardless of concomitant TPO-RA use.
conclusionsThis study demonstrates the real-world effectiveness and safety of fostamatinib in patients with ITP. Platelet count rose soon after fostamatinib initiation, within 1-2 weeks. Fostamatinib may enable reduction or discontinuation of GCs, even in patients with ITP refractory to TPO-RAs.
trial registrationUMIN000057096.
Indexed as
Identifiers
42552462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.